Trial · NCT07913685
The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
NCT07913685, Phase 4, Completed, Medical University of Bialystok
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes. Trials, record NCT07913685. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913685
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
- NCT number
- NCT07913685
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 83 participants, actual
- Lead sponsor
- Medical University of Bialystok
- Conditions
- Obesity & Overweight
- Interventions
- liraglutide, Low-calorie diet with dietician's monitoring
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in body weight (kg) | Week 12 | Observed change in body weight from baseline to week 12 in the group treated with liraglutide+LCD compared to dietary intervention alone. |
| Secondary | Proportion of subjects losing ≥ 5% of baseline body weight | Week 12 | Percentage of subjects losing at least 5% of baseline body weight after 12 weeks of treatment. |
| Secondary | Proportion of subjects losing ≥ 10% of baseline body weight | Week 12 | Percentage of subjects losing at least 10% of baseline body weight after 12 weeks of treatment. |
| Secondary | Change in waist circumference (cm) | Week 12 | Observed change in waist circumference from baseline to week 12. |
| Secondary | Change in insulin sensitivity measured in hyperinsulinemic euglycemic clamp | Week 12 | Observed change in insulin sensitivity measured in hyperinsulinemic euglycemic clamp from baseline to week 12. Insulin sensitivity will be expressed as whole-body glucose uptake normalized for fat-free mass. |
| Secondary | Change in indirect indices of insulin sensitivity: HOMA-IR | Week 12 | Observed change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) from baseline to week 12. |
| Secondary | Change in indirect indices of insulin sensitivity: Matsuda | Week 12 | Observed change in Matsuda index from baseline to week 12. |
| Secondary | Change in indirect indices of insulin sensitivity: FLAIS | Week 12 | Observed change in Fasting Laboratory Assessment of Insulin Sensitivity (FLAIS) index from baseline to week 12. FLAIS is an index of insulin sensitivity, calculated from RBC count, ALT, C-peptide, SHBG, adiponectin and IGFBP-1. Higher values of FLAIS reflect higher insulin sensitivity. |
| Secondary | Change in body composition: total fat mass (kg) | Week 12 | Observed change in total fat mass measured in dual-energy X-ray absorptiometry (DEXA) from baseline to week 12. |
| Secondary | Change in body composition: total lean mass (kg) | Week 12 | Observed change in total lean mass measured in dual-energy X-ray absorptiometry (DEXA) from baseline to week 12. |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913685
GET https://conductscience.org/api/trials/v1/NCT07913685/registered?page=2